NSG 5240 Advanced Pharmacology Midterm | Core
Blueprint | Verified Questions with Technical Rationales |
Instant Download Pdf
Advanced Prescriptive Authority Practice Bank | 100% Comprehensive | Nurse Practitioner
Certification Prep | Graded A+
Introduction
This specialized mid-term exam bank includes verified practice questions with correct
answers modeled after the NSG 5240 Advanced Pharmacology Graduate Curriculum.
Developed for Family Nurse Practitioner (FNP), Adult-Gerontology Primary Care Nurse
Practitioner (AGPCNP), and Acute Care Advanced Practice Nursing students, it covers core
prescriptive competencies. The material focuses heavily on advanced
pharmacokinetics/pharmacodynamics (PK/PD), CYP450 drug interactions, autonomic
nervous system agents, cardiovascular therapeutics, respiratory management,
endocrine pharmacology, and prescriptive safety rules. This resource is designed to
help advanced practice students master complex drug mechanisms, recognize dangerous
contraindications, evaluate lab markers, and confidently pass their graduate pharmacology
examinations.
Content Domains
Advanced Principles: PK/PD & CYP450 Drug Interactions (30 Questions)
Autonomic Nervous System & Cardiovascular Therapeutics (30 Questions)
Respiratory, Gastrointestinal, & Endocrine Pharmacology (30 Questions)
Neurology, Psychiatric, & Analgesic Agents (30 Questions)
Prescriptive Authority, Toxicology, & Special Populations (30 Questions)
Domains 1; PK/PD, CYP450, & Autonomic/Cardiovascular Systems)
,Q1. An elderly patient is prescribed a highly lipophilic medication. How does the age-
related physiological shift in body composition affect the volume of distribution
(\(V_{d}\)) and the elimination half-life (\(t_{1/2}\)) of this drug?
A) Decreased \(V_{d}\) and shortened elimination half-life.
B) Increased \(V_{d}\) and shortened elimination half-life.
C) Decreased \(V_{d}\) and prolonged elimination half-life.
D) Increased \(V_{d}\) and prolonged elimination half-life.
Rationale: As adults age, total body water and muscle mass decrease while adipose tissue
increases. Lipophilic drugs distribute extensively into this expanded fat compartment,
increasing the volume of distribution (\(V_{d}\)). Because half-life is directly proportional to
\(V_{d}\) (\(t_{1/2} = 0.693 \times V_d / Cl\)), the elimination half-life is significantly
prolonged, increasing the risk of drug accumulation.
Q2. A patient stabilizes on a continuous intravenous maintenance infusion of a drug.
If the drug follows first-order elimination kinetics, how many half-lives are required to
reach approximately 94% of steady-state plasma concentration?
A) 1 to 2 half-lives
B) 2 to 3 half-lives
C) 4 to 5 half-lives
D) 6 to 7 half-lives
Rationale: Under first-order kinetics, it takes approximately 4 to 5 half-lives to attain steady-
,state plasma concentrations (1 half-life = 50%, 2 = 75%, 3 = 87.5%, 4 = 93.75%, 5 =
96.9%). Conversely, when a drug is discontinued, it takes 4 to 5 half-lives to be completely
cleared from the system.
Q3. A nurse practitioner prescribes Rifampin, a potent Cytochrome P450 (CYP450)
3A4 enzyme inducer, to a patient who is currently stabilized on Warfarin. What is the
clinical consequence of this drug-drug interaction?
A) Enhanced therapeutic efficacy of Warfarin, causing an elevated INR and bleeding.
B) Accelerated metabolism of Warfarin, causing a decreased INR and subtherapeutic
thrombosis risk.
C) Displaced plasma protein binding, triggering acute Warfarin toxicity.
D) Reduced renal clearance of Warfarin, causing a delayed therapeutic response.
Rationale: CYP450 enzyme inducers like Rifampin stimulate the synthesis of hepatic
metabolic enzymes. This accelerates the biotransformation of substrate drugs like Warfarin.
As a result, plasma concentrations of Warfarin drop rapidly, leading to a subtherapeutic INR
and an increased risk of thromboembolism.
Q4. A patient is taking Amiodarone (a potent CYP3A4 inhibitor) and is initiated on
Simvastatin. Why must the nurse practitioner limit the maximum daily dose of
Simvastatin in this patient?
A) Amiodarone accelerates Simvastatin clearance, reducing its lipid-lowering efficacy.
B) Amiodarone inhibits Simvastatin metabolism, significantly increasing the risk of
, myopathy and rhabdomyolysis.
C) The combination causes competitive inhibition at the HMG-CoA reductase receptor site.
D) Simvastatin impairs the cardiac conduction stabilization properties of Amiodarone.
Rationale: CYP3A4 inhibitors like Amiodarone block the metabolic breakdown of statins
that rely heavily on this pathway (such as Simvastatin and Lovastatin). This increases
systemic drug exposure, raising the risk of statin-induced toxicities like severe myalgia,
myopathy, and life-threatening rhabdomyolysis.
Q5. Which of the following parameters describes a drug that acts as a "Prodrug"?
A) It demonstrates immediate maximum receptor affinity upon oral ingestion.
B) It bypasses hepatic first-pass elimination completely via sublingual administration.
C) It is pharmacologically inactive when administered and must be biotransformed
into an active metabolite by hepatic enzymes.
D) It exhibits zero-order elimination kinetics across all therapeutic dosing tiers.
Rationale: Prodrugs (e.g., enalapril, clopidogrel, vyvanse) are chemically inactive
compounds. They require hepatic biotransformation (often via specific CYP450 or esterase
enzymes) to convert into their active, therapeutic form inside the systemic circulation.
Q6. A patient presents with severe generic variation manifesting as a "CYP2D6 Poor
Metabolist." Which of the following opioid medications will show a severe lack of
analgesic efficacy in this patient?
A) Morphine
Blueprint | Verified Questions with Technical Rationales |
Instant Download Pdf
Advanced Prescriptive Authority Practice Bank | 100% Comprehensive | Nurse Practitioner
Certification Prep | Graded A+
Introduction
This specialized mid-term exam bank includes verified practice questions with correct
answers modeled after the NSG 5240 Advanced Pharmacology Graduate Curriculum.
Developed for Family Nurse Practitioner (FNP), Adult-Gerontology Primary Care Nurse
Practitioner (AGPCNP), and Acute Care Advanced Practice Nursing students, it covers core
prescriptive competencies. The material focuses heavily on advanced
pharmacokinetics/pharmacodynamics (PK/PD), CYP450 drug interactions, autonomic
nervous system agents, cardiovascular therapeutics, respiratory management,
endocrine pharmacology, and prescriptive safety rules. This resource is designed to
help advanced practice students master complex drug mechanisms, recognize dangerous
contraindications, evaluate lab markers, and confidently pass their graduate pharmacology
examinations.
Content Domains
Advanced Principles: PK/PD & CYP450 Drug Interactions (30 Questions)
Autonomic Nervous System & Cardiovascular Therapeutics (30 Questions)
Respiratory, Gastrointestinal, & Endocrine Pharmacology (30 Questions)
Neurology, Psychiatric, & Analgesic Agents (30 Questions)
Prescriptive Authority, Toxicology, & Special Populations (30 Questions)
Domains 1; PK/PD, CYP450, & Autonomic/Cardiovascular Systems)
,Q1. An elderly patient is prescribed a highly lipophilic medication. How does the age-
related physiological shift in body composition affect the volume of distribution
(\(V_{d}\)) and the elimination half-life (\(t_{1/2}\)) of this drug?
A) Decreased \(V_{d}\) and shortened elimination half-life.
B) Increased \(V_{d}\) and shortened elimination half-life.
C) Decreased \(V_{d}\) and prolonged elimination half-life.
D) Increased \(V_{d}\) and prolonged elimination half-life.
Rationale: As adults age, total body water and muscle mass decrease while adipose tissue
increases. Lipophilic drugs distribute extensively into this expanded fat compartment,
increasing the volume of distribution (\(V_{d}\)). Because half-life is directly proportional to
\(V_{d}\) (\(t_{1/2} = 0.693 \times V_d / Cl\)), the elimination half-life is significantly
prolonged, increasing the risk of drug accumulation.
Q2. A patient stabilizes on a continuous intravenous maintenance infusion of a drug.
If the drug follows first-order elimination kinetics, how many half-lives are required to
reach approximately 94% of steady-state plasma concentration?
A) 1 to 2 half-lives
B) 2 to 3 half-lives
C) 4 to 5 half-lives
D) 6 to 7 half-lives
Rationale: Under first-order kinetics, it takes approximately 4 to 5 half-lives to attain steady-
,state plasma concentrations (1 half-life = 50%, 2 = 75%, 3 = 87.5%, 4 = 93.75%, 5 =
96.9%). Conversely, when a drug is discontinued, it takes 4 to 5 half-lives to be completely
cleared from the system.
Q3. A nurse practitioner prescribes Rifampin, a potent Cytochrome P450 (CYP450)
3A4 enzyme inducer, to a patient who is currently stabilized on Warfarin. What is the
clinical consequence of this drug-drug interaction?
A) Enhanced therapeutic efficacy of Warfarin, causing an elevated INR and bleeding.
B) Accelerated metabolism of Warfarin, causing a decreased INR and subtherapeutic
thrombosis risk.
C) Displaced plasma protein binding, triggering acute Warfarin toxicity.
D) Reduced renal clearance of Warfarin, causing a delayed therapeutic response.
Rationale: CYP450 enzyme inducers like Rifampin stimulate the synthesis of hepatic
metabolic enzymes. This accelerates the biotransformation of substrate drugs like Warfarin.
As a result, plasma concentrations of Warfarin drop rapidly, leading to a subtherapeutic INR
and an increased risk of thromboembolism.
Q4. A patient is taking Amiodarone (a potent CYP3A4 inhibitor) and is initiated on
Simvastatin. Why must the nurse practitioner limit the maximum daily dose of
Simvastatin in this patient?
A) Amiodarone accelerates Simvastatin clearance, reducing its lipid-lowering efficacy.
B) Amiodarone inhibits Simvastatin metabolism, significantly increasing the risk of
, myopathy and rhabdomyolysis.
C) The combination causes competitive inhibition at the HMG-CoA reductase receptor site.
D) Simvastatin impairs the cardiac conduction stabilization properties of Amiodarone.
Rationale: CYP3A4 inhibitors like Amiodarone block the metabolic breakdown of statins
that rely heavily on this pathway (such as Simvastatin and Lovastatin). This increases
systemic drug exposure, raising the risk of statin-induced toxicities like severe myalgia,
myopathy, and life-threatening rhabdomyolysis.
Q5. Which of the following parameters describes a drug that acts as a "Prodrug"?
A) It demonstrates immediate maximum receptor affinity upon oral ingestion.
B) It bypasses hepatic first-pass elimination completely via sublingual administration.
C) It is pharmacologically inactive when administered and must be biotransformed
into an active metabolite by hepatic enzymes.
D) It exhibits zero-order elimination kinetics across all therapeutic dosing tiers.
Rationale: Prodrugs (e.g., enalapril, clopidogrel, vyvanse) are chemically inactive
compounds. They require hepatic biotransformation (often via specific CYP450 or esterase
enzymes) to convert into their active, therapeutic form inside the systemic circulation.
Q6. A patient presents with severe generic variation manifesting as a "CYP2D6 Poor
Metabolist." Which of the following opioid medications will show a severe lack of
analgesic efficacy in this patient?
A) Morphine
